Candel Therapeutics, Inc. (CADL) Q1 2026 Earnings
CADL·Reported May 14, 2026·Before market open
Diluted EPS came in at $-0.14, beat the $-0.22 consensus by $0.08.
Diluted EPS
$-0.14beat by $0.08
Consensus: $-0.22
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Candel Therapeutics, Inc.'s Q1 2026 earnings report.
Candel Therapeutics, Inc. (CADL) reported Q1 2026 earnings on May 14, 2026 before market open.
Candel Therapeutics, Inc. reported diluted EPS of $-0.14 for Q1 2026.
EPS beat the consensus estimate of $-0.22 by $0.08.
You can read the 8-K earnings release (0001193125-26-222892) and the 10-Q periodic report (0001193125-26-222904) directly on SEC EDGAR. The filing index links above go to sec.gov.